Class II — Potential Health Hazard

Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.

Sodium Chloride Inhalation Solution Recalled by Nephron Pharmaceuticals Corp. Due to Lack of Assurance of Sterility: Internal dye ingress...

Date: November 16, 2015
Company: Nephron Pharmaceuticals Corp.
Status: Terminated
Source: FDA (Device)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact Nephron Pharmaceuticals Corp. directly.

Affected Products

Sodium Chloride Inhalation Solution, USP 3%, 60 x 4 mL Sterile Unit-Dose Vials per carton, Rx Only, NDC 0487-9003-60. A vial contains sterile, preservation-free, clear, colorless, aqueous solution as labeled for induction of sputum production where specimen collection is indicated. For respiratory therapy, Solium Chloride Inhalation Solution USP, 3% is used in conjunction with a nebulizer

Quantity: 11,208 cartons

Why Was This Recalled?

Lack of Assurance of Sterility: Internal dye ingress test failure to assure the integrity of the vial.

Where Was This Sold?

This product was distributed to 35 states: AL, AZ, AR, CA, CO, CT, FL, GA, IL, KY, LA, MA, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, SC, TN, TX, UT, VT, VA, WA, WV, WI

Affected (35 states)Not affected

About Nephron Pharmaceuticals Corp.

Nephron Pharmaceuticals Corp. has 10 total recalls tracked by RecallDetector.

Related Recalls

Data sourced from the FDA (Device). Last updated March 26, 2026. View original report